Time-action profile of inhaled insulin

被引:0
|
作者
Heinemann, L
Traut, T
Heise, T
机构
[1] Dept. of Metab. Dis. and Nutrition, WHO Collaborating Ctr. for Diabetes, Heinrich-Heine-University, Düsseldorf
[2] Dept. of Metab. Dis. and Nutrition, Heinrich-Heine-Univ. of Dusseldorf, 40001 Düsseldorf
关键词
inhaled insulin; insulin pharmacokinetics; insulin pharmacodynamics; time-action profiles; bioavailability;
D O I
10.1002/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We compared the pharmacodynamics of insulin after inhalation of 99 U microcrystalline solid insulin and subcutaneous injection of 10 U regular insulin and intravenous injection of 5 U regular insulin. The time-action profiles of the three insulin administrations were studied in 11 healthy volunteers using the euglycaemic glucose clamp technique. The insulins were administered to each volunteer on three separate occasions in random order. Onset of action, assessed as glucose infusion rate, after insulin inhalation was substantially more rapid than after subcutaneous injection and half-maximal action was reached earlier (31 +/- 17 vs 54 +/- 12 min; p < 0.001). Maximal metabolic response was reached earlier after insulin inhalation in comparison to subcutaneous injection (108 +/- 49 vs 147 +/- 53 min; p < 0.001). The maximal glucose infusion rate after inhalation of insulin was lower than after subcutaneous insulin injection (6.2 +/- 2.4 vs 9.1 +/- 2.5 mg kg(-1) min(-1); p < 0.001). The glucose infusion rates in the first 60 min after inhalation were significantly greater than after insulin injection (area under the glucose infusion rate curve: 0.23 +/- 0.12 vs 0.13 +/- 0.08 g kg(-1) 60 min(-1); p < 0.001). However, the total metabolic effect after inhalation was significantly lower than after insulin injection (1.44 +/- 0.68 vs 1.90 +/- 0.47 g kg(-1) 360 min(-1); p < 0.001). Relative effectiveness of inhaled insulin calculated with regard to the data from the intravenous insulin application was 9.5 +/- 4.1 % and of the subcutaneous insulin application was 7.6 +/- 2.9 %. With its rapid onset of action, inhaled insulin might have potential for clinical use.
引用
收藏
页码:63 / 72
页数:10
相关论文
共 50 条
  • [1] Time-action profile of inhaled insulin
    Heise, T
    Traut, T
    Heinemann, L
    [J]. DIABETES, 1996, 45 : 819 - 819
  • [2] Time-action profile of inhaled insulin
    Heinemann, L
    Traut, T
    Heise, T
    [J]. DIABETOLOGIA, 1996, 39 : 89 - 89
  • [3] Time-action profile of an inhaled insulin preparation in comparison to insulin Lispro and regular insulin
    Bott, S
    Heinemann, L
    Rave, K
    Sha, S
    Willavize, SA
    Carroll, RS
    Gruber, S
    Lee, JD
    Heise, T
    [J]. DIABETOLOGIA, 2000, 43 : A46 - A46
  • [4] Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin
    Heise, T
    Rave, K
    Bott, S
    Sha, S
    Willavize, SA
    Carroll, RS
    Gruber, S
    Lee, JD
    Heinemann, L
    [J]. DIABETES, 2000, 49 : A10 - A10
  • [5] Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin
    Rave, K
    Bott, S
    Heinemann, L
    Sha, S
    Becker, RHA
    Willavize, SA
    Heise, T
    [J]. DIABETES CARE, 2005, 28 (05) : 1077 - 1082
  • [6] The variability and time-action profile of inhaled Technosphere/Insulin compares favorably to that of subcutaneous human regular insulin
    Boss, AH
    Heise, T
    Rave, K
    Cheatham, WW
    [J]. DIABETES, 2005, 54 : A88 - A88
  • [7] Inhaled Technosphere/Insulin: Favourable time-action profile and low variability in comparison to subcutaneous human regular insulin
    Cheatham, WW
    Rave, K
    Boss, AH
    Heise, T
    [J]. DIABETOLOGIA, 2005, 48 : A30 - A30
  • [8] Tolerability and Time-Action Profile of Technosphere Insulin in Pediatric Subjects
    Jones, Marisa C.
    Haller, Michael J.
    Ng, Savannah E.
    Bhavsar, Sunil
    Kaiserman, Kevin B.
    Krueger, John A.
    [J]. DIABETES, 2021, 70
  • [9] Time-action profile of the insulin analogue B28Asp
    Heinemann, L
    Kapitza, C
    Starke, AAR
    Heise, T
    [J]. DIABETIC MEDICINE, 1996, 13 (07) : 683 - 684
  • [10] Time-Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
    Haller, Michael J.
    Jones, Marisa C.
    Bhavsar, Sunil
    Kaiserman, Kevin B.
    [J]. DIABETES THERAPY, 2023, 14 (03) : 611 - 617